PRD-containing transcription factors - Revision history

Jstuelk at 17:31, 6 September 2018

2018-09-06T17:31:01Z

Jstuelk: /* Transcriptional activators */

2013-01-21T09:02:04Z

‎Transcriptional activators

Jstuelk at 08:59, 21 January 2013

2013-01-21T08:59:57Z

Jstuelk: /* Reviews */

2010-03-11T12:29:30Z

‎Reviews

Jstuelk: /* Reviews */

2010-01-20T19:11:02Z

‎Reviews

Jstuelk at 19:35, 24 November 2009

2009-11-24T19:35:26Z

Jstuelk at 19:35, 24 November 2009

2009-11-24T19:35:08Z

Jstuelk at 20:01, 31 August 2009

2009-08-31T20:01:35Z

Jstuelk at 20:00, 31 August 2009

2009-08-31T20:00:56Z

Jstuelk: /* Transcriptional activators */

2009-08-31T19:57:36Z

‎Transcriptional activators

← Older revision		Revision as of 17:31, 6 September 2018
Line 19:		Line 19:
	==Reviews==		==Reviews==
	<pubmed>9663674,11751049 17158705 12437213 23318733</pubmed>		<pubmed>9663674,11751049 17158705 12437213 23318733</pubmed>
		+
		+	==Back to [[Protein families]]==

@@ Line 15: / Line 15: @@
 * [[LicR]]: control of lichenan utilization (''[[licB]]-[[licC]]-[[licA]]-[[licH]]'')
 * [[ManR]]: control of mannose utilization (''[[manP]]-[[manA]]-[[yjdF]]'')
-* [[MtlR]]: control of mannitol utilization (''[[mtlA]]-[[mtlD]]'')
+* [[MtlR]]: control of mannitol utilization (''[[mtlA]]-[[mtlF]]-[[mtlD]]'')
 ==Reviews==
 <pubmed>9663674,11751049 17158705  12437213 23318733</pubmed>

← Older revision		Revision as of 08:59, 21 January 2013
Line 18:		Line 18:

	==Reviews==		==Reviews==
−	<pubmed>9663674,11751049 17158705 12437213 </pubmed>	+	<pubmed>9663674,11751049 17158705 12437213 23318733</pubmed>

← Older revision		Revision as of 12:29, 11 March 2010
Line 18:		Line 18:

	==Reviews==		==Reviews==
−	<pubmed>9663674,11751049 17158705 </pubmed>	+	<pubmed>9663674,11751049 17158705 12437213 </pubmed>

← Older revision		Revision as of 19:11, 20 January 2010
Line 18:		Line 18:

	==Reviews==		==Reviews==
−	<pubmed>9663674,11751049 </pubmed>	+	<pubmed>9663674,11751049 17158705 </pubmed>

@@ Line 1: / Line 1: @@
-These proteins exert positive control of gene expression by transcription activation or transcription antitermination. They regulate the uptake and utilization of specific sugars that are transported by the [[PTS|phosphotransferase system]]([[PTS]]).
+These proteins exert positive control of gene expression by transcription activation or transcription antitermination. They regulate the uptake and utilization of specific sugars that are transported by the [[PTS|phosphotransferase system]] ([[PTS]]).
 Their activity is negatively regulated in the absence of the specific inducer by phosphorylation by the corresponding Enzyme II of the [[PTS]]. This results in their inactivity. In the presence of the inducer, the phosphate group is drained to the transported substrate and the active regulators lead to expression of their corresponding catabolic operons.
 In addition, many PRD-containing regulators are positively controlled by [[PtsH|HPr]]-dependent phosphorylation. This phosphorylation occurs in the absence of glucose and other preferred carbon sources and is part of catabolite repression.

@@ Line 1: / Line 1: @@
-These proteins exert positive control of gene expression by transcription activation or transcription antitermination. They regulate the uptake and utilization of specific sugars that are transported by the phosphotransferase system (PTS).
+These proteins exert positive control of gene expression by transcription activation or transcription antitermination. They regulate the uptake and utilization of specific sugars that are transported by the [[PTS|phosphotransferase system]]([[PTS]]).
-Their activity is negatively regulated in the absence of the specific inducer by phosphorylation by the corresponding Enzyme II of the PTS. This results in their inactivity. In the presence of the inducer, the phosphate group is drained to the transported substrate and the active regulators lead to expression of their corresponding catabolic operons.
+Their activity is negatively regulated in the absence of the specific inducer by phosphorylation by the corresponding Enzyme II of the [[PTS]]. This results in their inactivity. In the presence of the inducer, the phosphate group is drained to the transported substrate and the active regulators lead to expression of their corresponding catabolic operons.
 In addition, many PRD-containing regulators are positively controlled by [[PtsH|HPr]]-dependent phosphorylation. This phosphorylation occurs in the absence of glucose and other preferred carbon sources and is part of catabolite repression.
-PRD: PTS regulation domain {{PubMed|9663674}}
+PRD: [[PTS]] regulation domain {{PubMed|9663674}}
 ==Transcriptional antiterminators==

@@ Line 17: / Line 17: @@
 * [[MtlR]]: control of mannitol utilization (''[[mtlA]]-[[mtlD]]'')
-==References==
+==Reviews==
 <pubmed>9663674,11751049  </pubmed>